Speciality: Rheumatology
Description:
A warm welcome to all the medical professionals in this interesting session of pioneering JAK science. We have Prof. Anand N. Malaviya, Dr Indrajit Agrawal, and Dr Sanjiv Kapoor to lead the session.
Immunological pathways play a crucial role in disease management especially in the case of rheumatological disease. Managing rheumatic diseases often becomes difficult and needs specialized attention which can be gained from this webinar.
The webinar will help in gaining important insights on JAK or Janus Kinase's family. The family includes Jak1, Jak2, Jak3, and Tyk2 which are involved in cell growth, development, and differentiation of the cells.
Get detailed information on the pathways involving JAK and how the JAK inhibiting drugs (tofacitinib) acts in controlling the progression of rheumatic diseases from this session.
Therefore, listen to the webinar, grab the knowledge that is shared and follow HiDoc for more such interesting webinar sessions.
See More Webinars @ Hidoc Webinars
See More Webinars @ Hidoc Webinars
1.
FDA Bans Red Dye No. 3 From Foods, Ingested Drugs
2.
Cancer patients want financial screening early in care, study finds
3.
Positive Trials; Malignancies Increasing in Younger Adults; Andre Braugher's Cancer Dx.
4.
November 2023, Medical Bulletin 04/.
5.
Radiation therapy for patients with breast cancer
1.
Cancer Diagnosis in 2025: Innovations, Education, and Evolving Clinical Strategies
2.
HPV Infection Review: Epidemiology, Risks, and Therapeutic Advances for Clinicians
3.
Mechanistic Insights into Abraxane, Verzenio, and the Management of Chemotherapy-Induced Tachycardia
4.
Revolutionizing Cancer Treatment: How Adoptive Cell Therapy is Overcoming Tumor Immune Evasion
5.
The latest Hematocrit: An Overview of Red Blood Cell Health
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
A Continuation to Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer
2.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VI
3.
Navigating the Complexities of Ph Negative ALL - Part X
4.
Redefining Treatment Pathways in Relapsed/Refractory Adult B-Cell ALL
5.
Navigating the Complexities of Ph Negative ALL - Part IX
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation